Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma

Patients with hepatocellular carcinoma (HCC) secondary to chronic liver disease often require invasive procedures, but frequently have thrombocytopenia. Lusutrombopag is an agonist of the thrombopoietin receptor that activates platelet production.

Source: Clinical Gastroenterology and Hepatology - March 19, 2020 Category: Gastroenterology Authors: Naim Alkhouri, Michio Imawari, Namiki Izumi, Yukio Osaki, Toshimitsu Ochiai, Takeshi Kano, Roy Bentley, Franco Trevisani Source Type: research